Saphenous vein graft (SVG) treatment and PCI in the setting of acute coronary syndromes are often related to distal embolization.
The background of the study is that distal embolization of thrombus/platelet aggregates is associated with worse immediate and long-term prognosis after PCI. The study's objective was to assess the efficacy of the MGuard stent, which combines a polymer-mesh sleeve attached to the external surface of a bare-metal stent, in preventing distal embolization during percutaneous coronary intervention (PCI).
#MGUARD TECH SUPPORT TRIAL#
InspireMD intends to pursue applications of this technology both for bare metal and drug eluting stents in coronary, carotid and peripheral artery procedures.July 1, 2010-Felipe Maia, MD, et al have published preliminary results from the INSPIRE trial of the MGuard coronary stent system (InspireMD Ltd., Tel Aviv, Israel) in Catheterization and Cardiovascular Interventions(2010:76:86–92). In addition to providing embolic protection and minimizing arterial injury, this promising technology can be an effective and uniform drug delivery mechanism with the help of the novel micron-level net for next generation drug eluting stents.
InspireMD's mission is to utilize its proprietary technology to make its products the industry standard for stents and to provide a superior solution to the key clinical issues of current stenting: restenosis, embolic showers, and late thrombosis. The company intends to apply its technology to develop products used in interventional cardiology and other vascular procedures. InspireMD is an innovative medical device company focusing on the development and commercialization of its proprietary stent system technology, MGuard™. The MGuard™ Coronary's innovative concept has enjoyed an enthusiastic welcome from leading interventional cardiologists around the world. The MGuard™ coronary stent provides permanent embolic protection, without complicating deliverability. The embolic protection is comprised of an ultra-thin polymer mesh sleeve that wraps the stent. MGuard™ presents a novel combination of a coronary stent merged with an embolic protection. “Real-world data of the MGuard coronary stent: Early data from the iMOS Registry”.“Six-month results of mesh covered stent implantation in ST-segment elevation myocardial infarction”.Cleverson Zukowski presented a case of “Residual Intra-stent thrombosis after Coronary Angioplasty in a Critical Artery of a Patient with Acute Coronary Syndrome” at 10:30 on Thursday, August 12th at the Sauce Hall of the Hilton Hotel.įurthermore, results from the MAGICAL study and the iMOS registry were displayed as posters
Gian Battista Danzi discussed the “New Methods to Treat Distal Embolization with the Micro-Mesh Covered Stent” at 10:30 on Wednesday, August 11th at the Pacara Hall of the Hilton Hotel. Some of the unique advantages of the MGuard stent were presented during the SOLACI congress: These improvements will directly benefit coronary patients in Latin America and throughout the world," said Eli Bar, CTO and VP R&D of InspireMD. In our testing we have experienced a 15% improvement in crossing profile and 45% improvement in pushability resistance. "We are very pleased with the flexibility and performance of the new delivery system. The new delivery system offers a state of the art design and superior deliverability. The new delivery system which has already been introduced in selected regions around the world will now make its launch in South America. is announcing the availability of a new and improved delivery system, for its MGuard™, coronary stent system.
0 kommentar(er)
